ADVISORY, Nov. 15, 2011 (GLOBE NEWSWIRE) --
MAP Pharmaceuticals, Inc. (MAPP), a biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology, will visit the NASDAQ MarketSite in New York City's Times Square. In honor of the occasion, Timothy Nelson, President and Chief Executive Officer of MAP Pharmaceuticals will officially ring The NASDAQ Stock Market Opening Bell.
NASDAQ MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
Wednesday, November 16th, 2011 – 9:15 a.m. to 9:30 a.m. ET
In MAP Pharmaceuticals office: Lisa Borland 650-440-2980 (cell)
The entire Opening Bell is available from 9:20 a.m. to 9:35 a.m. on the following:
Fiber Line (Encompass Media): 4463
Can also be found on Satellite:
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
If you have any questions, please contact Alex Honeysett (646 441 5211).
Facebook and Twitter:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/nasdaqomx
For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx
A live webcast of the NASDAQ Opening Bell will be available at:
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
MAP Pharmaceuticals, Inc:
MAP Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology.
The clinical development programs at MAP Pharmaceuticals include proprietary product candidates that address large market opportunities. These product candidates are designed to offer several benefits to patients compared to alternative therapies, including: quicker symptom relief, longer-lasting therapeutic benefit at lower doses, shorter administration time, enhanced safety profile and convenient, non-invasive delivery.
The Company is now developing LEVADEX, an orally inhaled investigational drug for the acute treatment of migraine. The U.S. Food and Drug Administration is currently reviewing the New Drug Application for LEVADEX for the potential acute treatment of migraine in adults. MAP Pharmaceuticals has entered into a collaboration agreement with Allergan, Inc. to co-promote LEVADEX to neurologists and pain specialists in the U.S. and Canada. The Company also applies its proprietary drug particle and inhalation technologies to generate new pipeline opportunities by enhancing the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.
About NASDAQ OMX:
The NASDAQ OMX Group, Inc. is the world's largest exchange company. It delivers trading, exchange technology and public company services across six continents, with more than 3,500 listed companies. NASDAQ OMX offers multiple capital raising solutions to companies around the globe, including its U.S. listings market, NASDAQ OMX Nordic, NASDAQ OMX Baltic, NASDAQ OMX first North, and the U.S. 144A sector. The company offers trading across multiple asset classes including equities, derivatives, debt, commodities, structured products and exchange-traded funds. NASDAQ OMX technology supports the operations of over 70 exchanges, clearing organizations and central securities depositories in more than 50 countries. NASDAQ OMX Nordic and NASDAQ OMX Baltic are not legal entities but describe the common offering from NASDAQ OMX exchanges in Helsinki, Copenhagen, Stockholm, Iceland, Tallinn, Riga, and Vilnius. For more information about NASDAQ OMX, visit http://www.nasdaqomx.com. *Please follow NASDAQ OMX on Facebook (http://www.facebook.com/pages/NASDAQ-OMX/108167527653) and Twitter (http://www.twitter.com/nasdaqomx).
In This StoryNDAQ
Nasdaq Press Center
Read the latest press releases, request a press kit, and get in touch with our press team.